Trial · NCT05267600
Outcomes24
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With CRoff at Week 36 | at week 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Cumulative OCS Dose | up to week 36 | mg/kg/day | MEAN | |
| SECONDARY | Number of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 36 | at week 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With CDA Who Remained Free of Relapse Through Week 36 | up to week 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With CRmin at Week 36 | at week 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Change From Baseline to Week 36 in the 24-Hour Average Itch NRS Score | up to week 36 | Only participants with an assessment at baseline and at week 36 are reported. | score on a scale | MEAN |
| SECONDARY | Changes From Baseline in the BPDAI Total Activity Score | up to week 36 | Only participants with an assessment at baseline and week 36 are reported here. | score on a scale | MEAN |
| SECONDARY | Time to CDA | up to week 36 | days | MEDIAN | |
| SECONDARY | Time to CR | up to week 36 | days | MEDIAN | |
| SECONDARY | Time to CRmin | up to week 36 | days | MEDIAN | |
| SECONDARY | Time to CRoff/PRoff | up to week 36 | days | MEDIAN | |
| SECONDARY | Time to CRoff | up to week 36 | days | MEDIAN | |
| SECONDARY | Time From CDA to Achieve Relapse | up to week 36 | Only participants achieving CDA are included in this section. | days | MEDIAN |
| SECONDARY | Number of Participants Who Receive Rescue Therapy Before Week 36 | at week 36 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | The AIS From the GTI | up to week 36 | Only participants with a GTI assessment at baseline and at week 36 are reported here. | score on a scale | MEAN |
| SECONDARY | The CWS From the GTI | up to week 36 | Only participants with a GTI assessment at baseline and at week 36 are reported here. | score on a scale | MEAN |
| SECONDARY | EQ-5D-5L VAS Scores Over Time | up to week 36 | Only participants with an assessment at baseline and at week 36 are reported here. | score on a scale | MEAN |
| SECONDARY | DLQI Scores Over Time | up to week 36 | Only participants with an assessment at baseline and at week 36 are reported here. | score on a scale | MEAN |
| SECONDARY | ABQoL Scores Over Time | up to week 36 | Only participants with an assessment at baseline and at week 36 are analyzed. | score on a scale | MEAN |
| SECONDARY | Efgartigimod Serum Concentrations | up to week 36 | The number analyzed differs from overall number analyzed because the following samples were excluded from analysis: Pre-dose samples that were taken after dosing on that day, samples taken outside the visit window, and when the study drug administration prior to the sample is missed. | ug/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05267600/outcomes